Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225


EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.

Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R.

J Clin Pathol. 2013 Feb;66(2):79-89. doi: 10.1136/jclinpath-2012-201194. Epub 2012 Nov 21. Review.


Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.

Peters MJ, Bowden JJ, Carpenter P, Lewis J, Solomon B.

Intern Med J. 2014 Jun;44(6):575-80. doi: 10.1111/imj.12449.


EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.

Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K.

Br J Cancer. 2006 Nov 20;95(10):1390-5. Epub 2006 Oct 24.


Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J.

J Clin Oncol. 2009 Jun 1;27(16):2653-9. doi: 10.1200/JCO.2008.17.3930. Epub 2009 May 4.


Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY.

Lung Cancer. 2012 Mar;75(3):321-5. doi: 10.1016/j.lungcan.2011.08.005. Epub 2011 Sep 17.


Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.

Righi L, Cuccurullo A, Vatrano S, Cappia S, Giachino D, De Giuli P, Ardine M, Novello S, Volante M, Scagliotti GV, Papotti M.

BMC Cancer. 2013 Mar 13;13:114. doi: 10.1186/1471-2407-13-114.


Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.

Yeo CD, Kim JW, Kim KH, Ha JH, Rhee CK, Kim SJ, Kim YK, Park CK, Lee SH, Park MS, Yim HW.

Lung Cancer. 2013 Aug;81(2):207-12. doi: 10.1016/j.lungcan.2013.04.023. Epub 2013 May 29.


Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer.

Hagiwara K, Kobayashi K.

Cancer Sci. 2013 Mar;104(3):291-7. doi: 10.1111/cas.12081. Epub 2013 Jan 24. Review.


The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.

Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, O'Byrne K.

J Clin Pathol. 2012 Jan;65(1):1-7. doi: 10.1136/jclinpath-2011-200275. Epub 2011 Oct 29. Review.


Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.


RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.

Tsai TH, Su KY, Wu SG, Chang YL, Luo SC, Jan IS, Yu CJ, Yu SL, Shih JY, Yang PC.

Eur Respir J. 2012 Mar;39(3):677-84. doi: 10.1183/09031936.00043511. Epub 2011 Jun 30.


Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.

Lozano MD, Zulueta JJ, Echeveste JI, Gúrpide A, Seijo LM, Martín-Algarra S, Del Barrio A, Pio R, Idoate MA, Labiano T, Perez-Gracia JL.

Oncologist. 2011;16(6):877-85. doi: 10.1634/theoncologist.2010-0155. Epub 2011 May 14.


Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).

Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M, Nakao S.

Br J Cancer. 2007 Sep 17;97(6):778-84.


Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Chu H, Zhong C, Xue G, Liang X, Wang J, Liu Y, Zhao S, Zhou Q, Bi J.

Oncol Rep. 2013 Nov;30(5):2311-5. doi: 10.3892/or.2013.2709. Epub 2013 Aug 29.


Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL.

J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757. Epub 2011 Jul 25.


Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.


Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.


A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients.

Liu Y, Liu B, Li XY, Li JJ, Qin HF, Tang CH, Guo WF, Hu HX, Li S, Chen CJ, Liu B, Gao HJ, Liu XQ.

J Exp Clin Cancer Res. 2011 Dec 6;30:111. doi: 10.1186/1756-9966-30-111.

Supplemental Content

Support Center